Haisco Pharmaceutical Group Co., Ltd.: history, ownership, mission, how it works & makes money

From a 2000 founding focused on R&D and manufacturing to a Shenzhen listing as 002653 in 2012, Haisco Pharmaceutical Group has grown into a vertically integrated drug maker that reported 3.72 billion yuan in revenue in 2024 and operates with an R&D team of over 700 researchers driving 66 drug varieties (21 first generics in China) and landmark innovations such as the 2021 launch of Ciprofol Injection; backed by a shareholder structure led by Wang Junmin and a 2025 non-public A‑share raise of up to 1.365 billion yuan to bolster R&D, the company's market capitalization reached about 60.68 billion yuan by December 2025 while its product mix across anesthesia, diabetes, oncology and parenteral nutrition, growing trailing‑12‑month revenue of 4.27 billion yuan (to Sept. 30, 2025) and strategic out‑licensing deals underscore how Haisco monetizes proprietary and high‑end generics through a sales force of over 1,000, nearly 5,000 management reps, commercial production bases, and an innovation‑led commercialization engine.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): Intro

• Founded in 2000, headquartered in Taizhou, Zhejiang, China.
• Listed on the Shenzhen Stock Exchange in 2012 (ticker 002653.SZ).
• Launched Ciprofol Injection in 2021 - China's first domestically developed brand-new intravenous anesthetic.
• By 2020 achieved revenue of 3.33 billion yuan and net profit of 637 million yuan.
• In 2025 announced a non-public A-share issuance to raise up to 1.365 billion yuan to strengthen R&D and commercialization.
• Market capitalization as of December 2025: approximately 60.68 billion yuan.

• Product segments:
  • APIs: Manufacture and sale of active pharmaceutical ingredients to domestic and international generic drug makers.
  • Finished Dosage Forms (FDFs): Branded and generic tablets, capsules, injections for hospital and retail channels.
  • Innovative drugs: Proprietary development (e.g., Ciprofol) and out-licensing/commercialization.
• Revenue streams:
  • Commercial sales of APIs and FDFs (domestic hospitals, distributors, export markets).
  • Sales from innovative products - initial contribution from Ciprofol post-2021 launch.
  • Contract manufacturing and toll-manufacturing services to third parties.
  • Potential licensing fees and milestone payments from partnerships for pipeline assets.
• R&D and pipeline commercialization:
  • R&D investment is a strategic focus; 2025 capital raise (up to 1.365 billion yuan) explicitly targets accelerating R&D and commercializing innovative drugs.
  • Pipeline progression includes anesthetic and other specialty therapeutic candidates (company emphasizes clinical development and regulatory approvals in China first, followed by potential overseas filings).

• Publicly traded on Shenzhen (002653.SZ) with institutional and retail shareholders; market cap ~60.68 billion yuan (Dec 2025).
• Management and board drive strategy toward higher-value innovative drugs while maintaining steady API/FDF cash flows.
• 2025 non-public A-share issuance planned to dilute/shareholder base modestly to raise up to 1.365 billion yuan for R&D - signaling an active capital allocation to innovation and capacity expansion.

• Manufacturing sites for APIs and FDFs with quality systems aligned to China NMPA standards and export requirements.
• Integrated supply chain from raw materials procurement to finished product packaging; capability for sterile injectables (critical for products like Ciprofol Injection).
• Export channels support revenue diversification beyond the domestic market.

• Balanced portfolio: stable cash-generating API/FDF business funds higher-margin innovative R&D.
• Proprietary innovation (Ciprofol) demonstrates ability to develop first-in-class / new molecular entities domestically.
• Capital-raising and reinvestment into R&D aim to accelerate pipeline commercialization and sustain long-term growth in market value.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): History

• Listing: Shenzhen Stock Exchange, ticker 002653.
• Core business: chemical generics, specialty drugs, and an expanding innovative drug pipeline.
• Strategic focus (post-2024): strengthen R&D and accelerate commercialization of in-house innovative candidates.

• The 2025 non-public A-share issuance is intended for specific investors, enabling targeted capital inflow while preserving managerial continuity - Wang Junmin remains the controlling shareholder despite the dilution to 37.75%.
• The strategic capital raise signals a priority on scaling R&D capability to move mid-to-late-stage assets toward clinical/commercial milestones and to support near-term working capital needs.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): Ownership Structure

• Mission: Improve patient outcomes by developing new and effective therapies across multiple therapeutic areas, addressing unmet medical needs and enhancing quality of life worldwide.
• Core values: integrity, innovation, excellence, patient-centricity, social responsibility, environmental stewardship, collaboration and continuous learning.
• Strategic focus: balance commercial generic and API production with increasing investment in novel-drug R&D to drive long-term sustainable growth.

• R&D orientation: Haisco targets therapeutic areas with high unmet need and leverages medicinal chemistry, process chemistry and formulation capabilities to progress internal and partnered candidates.
• Patient-centric operations: product safety, access, and post-market surveillance are integrated into manufacturing and commercialization decisions.
• Sustainability: programs to reduce environmental emissions in API production and to align growth with social responsibility goals.

• How Haisco makes money:
  • API and generic drug manufacturing and sales (volume-driven margins).
  • Finished-dosage formulations sold through domestic distribution and hospital channels.
  • Licensing, partnerships and milestone revenue from innovative-drug collaborations.
• Operational model highlights:
  • Integrated supply chain from API synthesis to finished product to manage cost and quality.
  • Investment in process optimization to improve gross margins on high-volume products.
  • Diversified portfolio balancing stable cash-generating generics with higher-risk/higher-reward R&D programs.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): Mission and Values

• Vertically integrated operations: in-house R&D, pilot and commercial manufacturing, quality control and direct sales distribution.
• R&D focus: innovative and high-end generics, lifecycle management and selected specialty molecules.
• Commercial footprint: national sales network covering major provinces and cities in China with field medical and sales personnel.
• Quality and regulatory alignment: domestic filing and first-generic launches prioritized to capture market exclusivity.

• Discovery & development - a centralized R&D center with over 700 scientific researchers (including PhDs and Masters) develops new formulations and high-end generics.
• Regulatory strategy - emphasis on first-generic approvals and rapid regulatory filings to secure market access and price advantages.
• Manufacturing - multiple production bases (including Haisco Pharmaceutical (Meishan) Co., Ltd.) handle non-sterile APIs and solid oral dosage commercial production.
• Commercialization - a large field force and management representative network implements medical-driven, academic-led and sales-landing programs to drive uptake.

• Finished dosage sales - branded generics and specialty formulations sold via hospital channels and retail pharmacies.
• API and contract manufacturing - commercial supply agreements and in-house production reduce COGS and capture upstream margin.
• First-generic capture - proprietary timing and approval strategy seeks premium volumes and limited competition in early market windows.
• Academic and KOL engagement - drives hospital formulary adoption and tender success via evidence generation and academic-led programs.

• Coverage: extensive provincial and municipal reach across China targeting tertiary, secondary hospitals and community healthcare.
• Field execution: over 1,000 sales staff supported by nearly 5,000 management representatives executing product launches, academic events and hospital tendering.
• Marketing model: 'Medical-driven, Academic-led, Sales-landing' - pilot projects to convert clinical advocacy into prescribing behavior and procurement wins.

• Haisco Pharmaceutical (Meishan) Co., Ltd. - commercial production base for non-sterile drug substances and solid dosage forms.
• Group structure supports scale: R&D hubs, multiple GMP-compliant plants and regional commercial subsidiaries to streamline distribution and regulatory alignment.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): How It Works

• Business model: discovery → clinical development → regulatory approval → manufacturing & commercialization.
• Listed status: publicly traded on the Shenzhen Stock Exchange (ticker 002653.SZ).
• Strategic focus: transition from a generics-heavy revenue base toward higher-margin innovative products.

• Product sales: high-end generics and proprietary innovative drugs sold domestically and in select export markets.
• Licensing/out‑licensing: milestone and royalty income from deals with international partners (e.g., TYK2 program).
• R&D value realization: de‑risking assets via clinical progress and partnerships to capture upfronts, equity value and future payments.

• Anesthesia & analgesia
• Diabetes mellitus and complications
• Oncology
• Parenteral nutrition

• Pipeline approach: multiple innovative drug programs progressing through clinical trials, designed to shift revenue mix toward patented, higher-margin products.
• Notable transaction: out‑licensing of a TYK2 inhibitor to Alumis - Alumis subsequently raised $210 million in funding and completed a Nasdaq IPO, illustrating the external commercial value of Haisco's assets.
• Commercialization strategy: leverage manufacturing and regulatory capabilities to support in‑house launches while partnering for international development and distribution where strategic.

• R&D investment and clinical advancement to create proprietary assets with exclusivity.
• Product diversification across established therapeutic areas to stabilize cash flows from generics while building innovative pipelines.
• Out‑licensing and strategic collaborations to accelerate global value capture and de‑risk development costs.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): How It Makes Money

• APIs and generic finished drugs sold to hospitals, distributors and multinational partners.
• Proprietary branded products in therapeutic areas with high unmet need.
• Contract manufacturing and CMO services for domestic and overseas pharmaceutical firms.
• Licensing deals and milestone-based income from global partnerships.